These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 29204994)
21. The new face of age-related macular degeneration. Giuliari GP; Ciardella AP Can J Ophthalmol; 2007 Aug; 42(4):629-30. PubMed ID: 17641716 [No Abstract] [Full Text] [Related]
22. Intravitreal avastin: the low cost alternative to lucentis? Rosenfeld PJ Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262 [No Abstract] [Full Text] [Related]
23. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. Campbell M; Doyle SL Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332 [TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration. Jonas JB; Tao Y; Rensch F Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119 [No Abstract] [Full Text] [Related]
25. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Emerson MV; Lauer AK BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122 [TBL] [Abstract][Full Text] [Related]
26. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use. Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Bom Aggio F; Eid Farah M; Melo GB Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511 [No Abstract] [Full Text] [Related]
28. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437 [TBL] [Abstract][Full Text] [Related]
29. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744 [TBL] [Abstract][Full Text] [Related]
30. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Moshfeghi AA Semin Ophthalmol; 2011 May; 26(3):139-48. PubMed ID: 21609227 [TBL] [Abstract][Full Text] [Related]
31. Inhibitors of ocular neovascularization: promises and potential problems. van Wijngaarden P; Coster DJ; Williams KA JAMA; 2005 Mar; 293(12):1509-13. PubMed ID: 15784876 [No Abstract] [Full Text] [Related]
32. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. El-Mollayess GM; Noureddine BN; Bashshur ZF Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219 [TBL] [Abstract][Full Text] [Related]
33. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. Teo KYC; Gillies M; Fraser-Bell S Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632 [TBL] [Abstract][Full Text] [Related]
34. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Gemenetzi M; Lotery AJ; Patel PJ Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization. Song JH; Moon KY; Lee SC; Kim SS Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325771 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab local complications. Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862 [No Abstract] [Full Text] [Related]
37. Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis. Reibaldi M; Fallico M; Avitabile T; Bonfiglio V; Russo A; Castellino N; Parisi G; Longo A; Pulvirenti A; Boscia F; Virgili G JAMA Ophthalmol; 2020 Jan; 138(1):50-57. PubMed ID: 31750861 [TBL] [Abstract][Full Text] [Related]